FOLH1 and prostate carcinoma: Results: Application is made to several clinically relevant specimens, including breast cancer (HER2, ER, and PR), prostate cancer (PSMA, P504S, basal cell, and CD8), Hodgkin’s lymphoma (CD15 and CD30), and melanoma (LAG3).